USP8 inhibitors could effectively antagonize the TGF-β/Smad signaling pathway in cancer cells, decrease the stability of TβRII and the number of TbRII + crEvs, thereby preventing tumor-induced exhaustion of CD8 + T cells and activating anticancer immunity, thus reducing cancer size and metastasis [57]. The gene discussed is CD8A; the disease is cancer.